Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye
Background: Many patients with essential blepharospasm also show dry eye signs and symptoms. Botulinum toxin A is an effective treatment for reducing spasms in these patients. In this investigation, the effect of botulinum toxin A injections on tear function and on the morphology of the ocular surfa...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2003-01, Vol.87 (1), p.54-56 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 56 |
|---|---|
| container_issue | 1 |
| container_start_page | 54 |
| container_title | British journal of ophthalmology |
| container_volume | 87 |
| creator | Horwath-Winter, J Bergloeff, J Floegel, I Haller-Schober, E-M Schmut, O |
| description | Background: Many patients with essential blepharospasm also show dry eye signs and symptoms. Botulinum toxin A is an effective treatment for reducing spasms in these patients. In this investigation, the effect of botulinum toxin A injections on tear function and on the morphology of the ocular surface in patients suffering from blepharospasm in combination with a dry eye syndrome was investigated. Methods: Botulinum toxin A injections were applied to 16 patients with blepharospasm. All patients complained of dry eye symptoms and had reduced tear break up time values. A subjective questionnaire and ocular examinations including tear break up time, Schirmer test without local anaesthesia, and rose bengal staining were evaluated before, 1 week, 1 month, and 3 months after injection. Impression cytology was performed before, 1 month, and 3 months after botulinum toxin A treatment. Results: Although all patients were relieved of blepharospasm after botulinum toxin injections, only three noticed an improvement in dry eye symptoms. Eight patients noticed no difference and five complained of worsening. Tear break up time was found to be increased 1 week and 1 month after injections. Schirmer test measurements were reduced up to 3 months. Rose bengal staining slightly increased 1 week after injections. Impression cytology showed no definite change in conjunctival cell morphology 1 month and 3 months after botulinum toxin A injections. Conclusion: In the patients presented here suffering from blepharospasm and dry eye, botulinum toxin A injections were effective in relieving blepharospasm but were not successful in treating dry eye syndrome. |
| doi_str_mv | 10.1136/bjo.87.1.54 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1771456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A96391857</galeid><sourcerecordid>A96391857</sourcerecordid><originalsourceid>FETCH-LOGICAL-b645t-b77f61028735afdc462cb59451ec153a58d24731b06b7461c41946c50a9c1b0a3</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EomnhxB1ZQnCBDZ5df-xekEJEC1IFHKAHLpbXa6cOu3Zq71bNv8dRohSkCvkwnplHr96ZQegFkDlAxd-36zCvxRzmjD5CM6C8LkoimsdoRggRBQCHE3Sa0jqnJQfxFJ1ASeu65NUMff8Yxql3fhrwGO6cxws8RqPGwfgR53SjRpe_CafJWhOdX2Ebw4Db3myuVQxpo9KAle9wF7fYbM0z9MSqPpnnh3iGfp5_-rH8XFx-u_iyXFwWLadsLFohLAdS1qJiynaa8lK3rKEMjAZWKVZ3JRUVtIS3gnLQFBrKNSOq0bmoqjP0Ya-7mdrBdDqbjKqXm-gGFbcyKCf_7Xh3LVfhVoIQQBnPAq8OAjHcTCaNch2m6LPnHdIQ2K0rU-_21Er1RjpvQxbTK-NN1gzeWJfLi4ZXDdRMZLx4AM-vM4PTD_Fv97zOq0zR2OMAQOTuujJfV9ZCgmQ00y__nvmePZwzA68PgEpa9TYqr1265ygt2W7lR5sujebu2Ffxt-SiEkx-vVrKX-dwUZf0SpLMv9nz7bD-r8M_-R_IKA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779010002</pqid></control><display><type>article</type><title>Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye</title><source>MEDLINE</source><source>PubMed (Medline)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Horwath-Winter, J ; Bergloeff, J ; Floegel, I ; Haller-Schober, E-M ; Schmut, O</creator><creatorcontrib>Horwath-Winter, J ; Bergloeff, J ; Floegel, I ; Haller-Schober, E-M ; Schmut, O</creatorcontrib><description>Background: Many patients with essential blepharospasm also show dry eye signs and symptoms. Botulinum toxin A is an effective treatment for reducing spasms in these patients. In this investigation, the effect of botulinum toxin A injections on tear function and on the morphology of the ocular surface in patients suffering from blepharospasm in combination with a dry eye syndrome was investigated. Methods: Botulinum toxin A injections were applied to 16 patients with blepharospasm. All patients complained of dry eye symptoms and had reduced tear break up time values. A subjective questionnaire and ocular examinations including tear break up time, Schirmer test without local anaesthesia, and rose bengal staining were evaluated before, 1 week, 1 month, and 3 months after injection. Impression cytology was performed before, 1 month, and 3 months after botulinum toxin A treatment. Results: Although all patients were relieved of blepharospasm after botulinum toxin injections, only three noticed an improvement in dry eye symptoms. Eight patients noticed no difference and five complained of worsening. Tear break up time was found to be increased 1 week and 1 month after injections. Schirmer test measurements were reduced up to 3 months. Rose bengal staining slightly increased 1 week after injections. Impression cytology showed no definite change in conjunctival cell morphology 1 month and 3 months after botulinum toxin A injections. Conclusion: In the patients presented here suffering from blepharospasm and dry eye, botulinum toxin A injections were effective in relieving blepharospasm but were not successful in treating dry eye syndrome.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjo.87.1.54</identifier><identifier>PMID: 12488263</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; blepharospasm ; Blepharospasm - drug therapy ; Blepharospasm - pathology ; botulinum toxin A ; Botulinum Toxins, Type A - therapeutic use ; Botulism ; Cellular biology ; Cellulose acetate ; Clinical Science ; Conjunctiva - pathology ; dry eye syndrome ; Dry eye syndromes ; Dry Eye Syndromes - drug therapy ; Dry Eye Syndromes - pathology ; Epithelium - pathology ; Eye ; Eyelid diseases ; Female ; Humans ; Injections ; Male ; Medical sciences ; Metaplasia - pathology ; Middle Aged ; Morphology ; Neuromuscular Agents - therapeutic use ; Ophthalmology ; Patients ; Pharmacology. Drug treatments ; Tears - metabolism</subject><ispartof>British journal of ophthalmology, 2003-01, Vol.87 (1), p.54-56</ispartof><rights>Copyright 2003 British Journal of Ophthalmology</rights><rights>2003 INIST-CNRS</rights><rights>COPYRIGHT 2003 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2003 Copyright 2003 British Journal of Ophthalmology</rights><rights>Copyright © Copyright 2003 British Journal of Ophthalmology 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b645t-b77f61028735afdc462cb59451ec153a58d24731b06b7461c41946c50a9c1b0a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771456/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771456/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14425287$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12488263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horwath-Winter, J</creatorcontrib><creatorcontrib>Bergloeff, J</creatorcontrib><creatorcontrib>Floegel, I</creatorcontrib><creatorcontrib>Haller-Schober, E-M</creatorcontrib><creatorcontrib>Schmut, O</creatorcontrib><title>Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>Background: Many patients with essential blepharospasm also show dry eye signs and symptoms. Botulinum toxin A is an effective treatment for reducing spasms in these patients. In this investigation, the effect of botulinum toxin A injections on tear function and on the morphology of the ocular surface in patients suffering from blepharospasm in combination with a dry eye syndrome was investigated. Methods: Botulinum toxin A injections were applied to 16 patients with blepharospasm. All patients complained of dry eye symptoms and had reduced tear break up time values. A subjective questionnaire and ocular examinations including tear break up time, Schirmer test without local anaesthesia, and rose bengal staining were evaluated before, 1 week, 1 month, and 3 months after injection. Impression cytology was performed before, 1 month, and 3 months after botulinum toxin A treatment. Results: Although all patients were relieved of blepharospasm after botulinum toxin injections, only three noticed an improvement in dry eye symptoms. Eight patients noticed no difference and five complained of worsening. Tear break up time was found to be increased 1 week and 1 month after injections. Schirmer test measurements were reduced up to 3 months. Rose bengal staining slightly increased 1 week after injections. Impression cytology showed no definite change in conjunctival cell morphology 1 month and 3 months after botulinum toxin A injections. Conclusion: In the patients presented here suffering from blepharospasm and dry eye, botulinum toxin A injections were effective in relieving blepharospasm but were not successful in treating dry eye syndrome.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>blepharospasm</subject><subject>Blepharospasm - drug therapy</subject><subject>Blepharospasm - pathology</subject><subject>botulinum toxin A</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Botulism</subject><subject>Cellular biology</subject><subject>Cellulose acetate</subject><subject>Clinical Science</subject><subject>Conjunctiva - pathology</subject><subject>dry eye syndrome</subject><subject>Dry eye syndromes</subject><subject>Dry Eye Syndromes - drug therapy</subject><subject>Dry Eye Syndromes - pathology</subject><subject>Epithelium - pathology</subject><subject>Eye</subject><subject>Eyelid diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metaplasia - pathology</subject><subject>Middle Aged</subject><subject>Morphology</subject><subject>Neuromuscular Agents - therapeutic use</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Tears - metabolism</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1vEzEQhi0EomnhxB1ZQnCBDZ5df-xekEJEC1IFHKAHLpbXa6cOu3Zq71bNv8dRohSkCvkwnplHr96ZQegFkDlAxd-36zCvxRzmjD5CM6C8LkoimsdoRggRBQCHE3Sa0jqnJQfxFJ1ASeu65NUMff8Yxql3fhrwGO6cxws8RqPGwfgR53SjRpe_CafJWhOdX2Ebw4Db3myuVQxpo9KAle9wF7fYbM0z9MSqPpnnh3iGfp5_-rH8XFx-u_iyXFwWLadsLFohLAdS1qJiynaa8lK3rKEMjAZWKVZ3JRUVtIS3gnLQFBrKNSOq0bmoqjP0Ya-7mdrBdDqbjKqXm-gGFbcyKCf_7Xh3LVfhVoIQQBnPAq8OAjHcTCaNch2m6LPnHdIQ2K0rU-_21Er1RjpvQxbTK-NN1gzeWJfLi4ZXDdRMZLx4AM-vM4PTD_Fv97zOq0zR2OMAQOTuujJfV9ZCgmQ00y__nvmePZwzA68PgEpa9TYqr1265ygt2W7lR5sujebu2Ffxt-SiEkx-vVrKX-dwUZf0SpLMv9nz7bD-r8M_-R_IKA</recordid><startdate>200301</startdate><enddate>200301</enddate><creator>Horwath-Winter, J</creator><creator>Bergloeff, J</creator><creator>Floegel, I</creator><creator>Haller-Schober, E-M</creator><creator>Schmut, O</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>Copyright 2003 British Journal of Ophthalmology</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>200301</creationdate><title>Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye</title><author>Horwath-Winter, J ; Bergloeff, J ; Floegel, I ; Haller-Schober, E-M ; Schmut, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b645t-b77f61028735afdc462cb59451ec153a58d24731b06b7461c41946c50a9c1b0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>blepharospasm</topic><topic>Blepharospasm - drug therapy</topic><topic>Blepharospasm - pathology</topic><topic>botulinum toxin A</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Botulism</topic><topic>Cellular biology</topic><topic>Cellulose acetate</topic><topic>Clinical Science</topic><topic>Conjunctiva - pathology</topic><topic>dry eye syndrome</topic><topic>Dry eye syndromes</topic><topic>Dry Eye Syndromes - drug therapy</topic><topic>Dry Eye Syndromes - pathology</topic><topic>Epithelium - pathology</topic><topic>Eye</topic><topic>Eyelid diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metaplasia - pathology</topic><topic>Middle Aged</topic><topic>Morphology</topic><topic>Neuromuscular Agents - therapeutic use</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Tears - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horwath-Winter, J</creatorcontrib><creatorcontrib>Bergloeff, J</creatorcontrib><creatorcontrib>Floegel, I</creatorcontrib><creatorcontrib>Haller-Schober, E-M</creatorcontrib><creatorcontrib>Schmut, O</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horwath-Winter, J</au><au>Bergloeff, J</au><au>Floegel, I</au><au>Haller-Schober, E-M</au><au>Schmut, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2003-01</date><risdate>2003</risdate><volume>87</volume><issue>1</issue><spage>54</spage><epage>56</epage><pages>54-56</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>Background: Many patients with essential blepharospasm also show dry eye signs and symptoms. Botulinum toxin A is an effective treatment for reducing spasms in these patients. In this investigation, the effect of botulinum toxin A injections on tear function and on the morphology of the ocular surface in patients suffering from blepharospasm in combination with a dry eye syndrome was investigated. Methods: Botulinum toxin A injections were applied to 16 patients with blepharospasm. All patients complained of dry eye symptoms and had reduced tear break up time values. A subjective questionnaire and ocular examinations including tear break up time, Schirmer test without local anaesthesia, and rose bengal staining were evaluated before, 1 week, 1 month, and 3 months after injection. Impression cytology was performed before, 1 month, and 3 months after botulinum toxin A treatment. Results: Although all patients were relieved of blepharospasm after botulinum toxin injections, only three noticed an improvement in dry eye symptoms. Eight patients noticed no difference and five complained of worsening. Tear break up time was found to be increased 1 week and 1 month after injections. Schirmer test measurements were reduced up to 3 months. Rose bengal staining slightly increased 1 week after injections. Impression cytology showed no definite change in conjunctival cell morphology 1 month and 3 months after botulinum toxin A injections. Conclusion: In the patients presented here suffering from blepharospasm and dry eye, botulinum toxin A injections were effective in relieving blepharospasm but were not successful in treating dry eye syndrome.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>12488263</pmid><doi>10.1136/bjo.87.1.54</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2003-01, Vol.87 (1), p.54-56 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1771456 |
| source | MEDLINE; PubMed (Medline); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences blepharospasm Blepharospasm - drug therapy Blepharospasm - pathology botulinum toxin A Botulinum Toxins, Type A - therapeutic use Botulism Cellular biology Cellulose acetate Clinical Science Conjunctiva - pathology dry eye syndrome Dry eye syndromes Dry Eye Syndromes - drug therapy Dry Eye Syndromes - pathology Epithelium - pathology Eye Eyelid diseases Female Humans Injections Male Medical sciences Metaplasia - pathology Middle Aged Morphology Neuromuscular Agents - therapeutic use Ophthalmology Patients Pharmacology. Drug treatments Tears - metabolism |
| title | Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A45%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20toxin%20A%20treatment%20in%20patients%20suffering%20from%20blepharospasm%20and%20dry%20eye&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Horwath-Winter,%20J&rft.date=2003-01&rft.volume=87&rft.issue=1&rft.spage=54&rft.epage=56&rft.pages=54-56&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjo.87.1.54&rft_dat=%3Cgale_pubme%3EA96391857%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779010002&rft_id=info:pmid/12488263&rft_galeid=A96391857&rfr_iscdi=true |